Ken Griffin Innate Pharma Sa Put Options Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding IPHA
# of Institutions
10Shares Held
81.6KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY53.6KShares$97,4860.0% of portfolio
-
Ubs Group Ag4.8KShares$8,7300.0% of portfolio
-
Gamma Investing LLC Foster City, CA2.28KShares$4,1510.0% of portfolio
-
Rhumbline Advisers Boston, MA470Shares$8550.0% of portfolio
-
Barclays PLC London, X0307Shares$5580.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $145M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...